How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

907 results for

Acne Vulgaris Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Effectiveness of topical or oral pharmacological and physical interventions as maintenance treatment for acne vulgaris

Effectiveness of topical or oral pharmacological and physical interventions as maintenance treatment for acne vulgaris Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) the same results as the fixed-effect model. For further details, see the and to pre-clinical meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one

2020 PROSPERO

42. Referral to specialist care for people with acne vulgaris

Referral to specialist care for people with acne vulgaris Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr (...) meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we will correct the total number of control animals in the meta-analysis

2020 PROSPERO

43. Severe Acne Vulgaris Management

Severe Acne Vulgaris Management Severe Acne Vulgaris Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Severe Acne Vulgaris (...) Management Severe Acne Vulgaris Management Aka: Severe Acne Vulgaris Management , Cystic Acne From Related Chapters II. Indications Moderate to severe Nodular, pustular, or cystic III. Management: Step 1 - Incorporate Moderate Acne Vulgaris Management See Continue Continue (e.g. ) Continue topical antibiotic (e.g. T) May combine with (e.g. ) Consider IV. Management: Step 2 - Start Oral Antibiotics ral Do not anticipate an effect for 6 to 8 weeks Continue antibiotic for minimum of 6 months should be used

2018 FP Notebook

44. Moderate Acne Vulgaris Management

Moderate Acne Vulgaris Management Moderate Acne Vulgaris Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Moderate Acne (...) Vulgaris Management Moderate Acne Vulgaris Management Aka: Moderate Acne Vulgaris Management , Acne Vulgaris Pharmacologic Management From Related Chapters II. Indication Mild to moderate Inflammatory Comedonal III. Management: Step 1 - OTC topical medications (Self-directed treatment) Approach Patient typically presents already using Most providers start at step 2 Indications Comedones Preparations wash (e.g. Cetaphil) daily Topical 2.5% gel in morning 2.5% is as effective as 5-10% Lower strength

2018 FP Notebook

45. Adjunctive Acne Vulgaris Management

Adjunctive Acne Vulgaris Management Adjunctive Acne Vulgaris Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Adjunctive (...) Acne Vulgaris Management Adjunctive Acne Vulgaris Management Aka: Adjunctive Acne Vulgaris Management From Related Chapters II. Management: Options for women Change if already taking one Increase (50ug minimum) Decrease to low androgenic with low androgenic Norlutin Aygestin Demulen Zovia Indications: Women with androgen hypersecretion increased -S increased Dose: 50 to 200 mg orally daily III. Management: Inflammatory Acne Visible decreases inflammatory acne s Moderate to high potency agents

2018 FP Notebook

46. Acne Vulgaris Management

Acne Vulgaris Management Acne Vulgaris Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Acne Vulgaris Management Acne (...) Vulgaris Management Aka: Acne Vulgaris Management , Acne Vulgaris Non-Pharmacologic Management From Related Chapters II. Management: Exacerbating factors to avoid Medications that exacerbate acne Androgenic steroids (e.g. , Testosterone s s ( ) Environment Hot Greasy (fast-food kitchen, garage) Oil based Cosmetics Cosmetics with Lanolin or petroleum jelly Oil based s or s Emotional Stress Physical Pressure (acne mechanica) Tight chinstrap Helmet III. Management: Myths (non-causes of Acne Vulgaris

2018 FP Notebook

47. A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2017 Clinical Trials

48. Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03303170 Recruitment Status : Completed First Posted : October 5, 2017 Last Update Posted : May 23, 2018 Sponsor: Sebacia

2017 Clinical Trials

49. A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03307577 Recruitment Status : Recruiting First Posted : October 11, 2017 Last

2017 Clinical Trials

50. Treatment of Moderate-to-severe Acne Vulgaris in a Hispanic Population: A Post-hoc Analysis of the Efficacy and Tolerability of Clindamycin 1.2%/Benzoyl Peroxide 3.75% Gel Full Text available with Trip Pro

Treatment of Moderate-to-severe Acne Vulgaris in a Hispanic Population: A Post-hoc Analysis of the Efficacy and Tolerability of Clindamycin 1.2%/Benzoyl Peroxide 3.75% Gel Background: Acne vulgaris (acne) is highly prevalent in the Hispanic population as it is in other racial/ethnic groups. While nuances in the presentation, quality-of-life impact, and approach to therapy of acne have been reported in various racial ethnic groups and skin types, data on the Hispanic population are limited (...) , and yet they are the fastest growing population in the United States. Potential for irritation, dryness, and pigmentary alteration (due to acne and/or treatment) are key concerns in the management of acne in Hispanic populations. Evaluation of the efficacy and tolerability of topical therapies in this growing segment of the population is therefore important. Methods: A post-hoc analysis of efficacy and cutaneous tolerability in 136 Hispanic subjects receiving clindamycin phosphate 1.2%/benzoyl

2017 The Journal of clinical and aesthetic dermatology Controlled trial quality: uncertain

51. Skin Surface pH in Acne Vulgaris: Insights from an Observational Study and Review of the Literature Full Text available with Trip Pro

Skin Surface pH in Acne Vulgaris: Insights from an Observational Study and Review of the Literature OBJECTIVE: Recurrent and chronic course of acne vulgaris, despite effect-proven therapies, point to an underfocused aspect in its pathogenesis and management. This study aims to assess in subjects with and without acne, the skin surface pH, a parameter that cumulatively represents functioning of various units of skin, including the barrier. METHODS: A total of 200 patients with acne and 200 age (...) - and sex-matched controls were included. Under basal conditions, facial skin pH was derived from five sites using a skin pH-meter. The relation between skin pH and acne was evaluated according to sex. RESULTS: There were more subjects with normal skin pH in the control group compared to the case group, and the majority of acne occurrences in the case group were related to high skin pH (p=0.000). Mean pH among cases was higher than normal reference value (pH 4.5-5.5 for women, 4-5.5 for men

2017 The Journal of clinical and aesthetic dermatology

52. Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03361345 Recruitment

2017 Clinical Trials

53. A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03271021

2017 Clinical Trials

54. Efficacy of Acupuncture Combined With Moving Cupping and Ear Point Tapping for Moderate and Severe Acne Vulgaris

Efficacy of Acupuncture Combined With Moving Cupping and Ear Point Tapping for Moderate and Severe Acne Vulgaris Efficacy of Acupuncture Combined With Moving Cupping and Ear Point Tapping for Moderate and Severe Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Efficacy of Acupuncture Combined With Moving Cupping and Ear Point Tapping for Moderate and Severe Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

55. A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03292640 Recruitment Status : Completed First Posted : September 25, 2017 Last Update Posted : August 16, 2018

2017 Clinical Trials

56. A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris (DFD-03) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03290027 Recruitment Status : Completed First Posted : September 21, 2017 Last Update Posted : August 16, 2018 Sponsor: Dr. Reddy's Laboratories Limited Information

2017 Clinical Trials

57. Use of adjunctive oral corticosteroid agents to oral isotretinoin for treatment of severe acne vulgaris

Use of adjunctive oral corticosteroid agents to oral isotretinoin for treatment of severe acne vulgaris Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) , see the and to pre-clinical meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we will correct the total number of control

2019 PROSPERO

58. Information and support for people with acne vulgaris and their parents or carers

Information and support for people with acne vulgaris and their parents or carers Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email (...) meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we will correct the total number of control animals in the meta-analysis

2019 PROSPERO

59. What skin care advice is appropriate for people with acne vulgaris?

What skin care advice is appropriate for people with acne vulgaris? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g (...) meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we will correct the total number of control animals in the meta-analysis

2019 PROSPERO

60. What are the risk factors for scarring resulting from acne vulgaris?

What are the risk factors for scarring resulting from acne vulgaris? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (...) meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we will correct the total number of control animals in the meta-analysis

2019 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>